APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants

The V179I substitution in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) is selected in humans or mouse models treated with certain nonnucleoside reverse transcriptase inhibitors (NNRTIs). While it is often observed together with other NNRTI resistance mutations, V179I does n...

Descripción completa

Detalles Bibliográficos
Autores principales: Dwivedi, Richa, Wang, Youya, Kline, Christopher, Fischer, Douglas K., Ambrose, Zandrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364801/
https://www.ncbi.nlm.nih.gov/pubmed/35957953
http://dx.doi.org/10.3389/fviro.2022.919825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364801/
https://www.ncbi.nlm.nih.gov/pubmed/35957953
http://dx.doi.org/10.3389/fviro.2022.919825

Ejemplares similares